Intellia Therapeutics raises $70 mln

Intellia Therapeutics said Tuesday it closed a $70 million Series B investment round led by OrbiMed HealthCare Fund Management. Additional investors included Fidelity Management and Research Company, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and other mutual fund and healthcare investors. Cambridge, Massachusetts-based Intellia is a gene-editing company.

North AmericaUSBriefs